Immune-checkpoint inhibitors and chimeric antigen receptor (CAR) T cells are
revolutionizing oncology and haematology practice. With these and other immunotherapies …

Immunotherapies have revolutionized the treatment paradigms of various types of cancers.
However, most of these immunomodulatory strategies focus on harnessing adaptive …

CD40 is a cell-surface member of the TNF (tumor necrosis factor) receptor superfamily.
Upon activation, CD40 can license dendritic cells to promote antitumor T cell activation and …

Most tumors are unresponsive to immune checkpoint blockade, especially if deep
immunosuppression in the tumor develops prior to and prevents T cell immunosurveillance …

Gliomas are brain tumors characterized by an immunosuppressive microenvironment.
Immunostimulatory agonistic CD40 antibodies (αCD40) are in clinical development for solid …

Systemic immunotherapies such as immune checkpoint blockade targeted at PD (L) 1 and
CTLA4 have demonstrated their ability to provide durable tumor responses and long-term …

Following the clinical success of immune checkpoint antibodies targeting CTLA-4, PD-1 or
PD-L1 in cancer treatment, bispecific antibodies are now emerging as a growing class of …

Background Recently, cancer immunotherapy has become standard for cancer treatment.
Immunotherapy not only treats primary tumors, but also prevents metastasis and recurrence …

Background & Aims While cholangiocarcinomas (CCAs) commonly express programmed
cell death 1 (PD-1) and its ligand (PD-L1), they respond poorly to immune checkpoint …

Depletion of immunosuppressive tumor-associated macrophages (TAMs) or reprogramming
toward a proinflammatory activation state represent different strategies to therapeutically …